SCHEMBL6014622

SCHEMBL6014622

[N-]=[N+]=NS(=O)(=O)c1ccc(CCCCCCc2ccc(S(=O)(=O)N=[N+]=[N-])cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 11/20 0.45
MGLL Q99685 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
CA9 Q16790 5/20 0.38
BCL2L1 Q07817 1/20 0.37
BAK1 Q16611 1/20 0.37
CA12 O43570 4/20 0.36
CA1 P00915 4/20 0.36
CA4 P22748 2/20 0.35
CA6 P23280 2/20 0.35
CA5A P35218 2/20 0.35
CA7 P43166 2/20 0.35
CA14 Q9ULX7 2/20 0.35
CA5B Q9Y2D0 2/20 0.35
F2 P00734 1/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
TSHR P16473 1/20 0.34
TMPRSS4 Q9NRS4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL969243 0.92 CA2 (0.55) CA2SMN1; SMN2CA9CA12CA1
SCHEMBL28459415 0.92 CA2 (0.55) CA2SMN1; SMN2CA9CA12CA1
SCHEMBL17704474 0.92 MAOB (0.42) CA2MGLLBCL2L1BAK1CA12
SCHEMBL11595972 0.88 CA2 (0.56) CA2SMN1; SMN2CA9CA12CA1
SCHEMBL14798577 0.84 CA2 (0.39) CA2MGLLSMN1; SMN2CA9BCL2L1
SCHEMBL14797979 0.84 CA2 (0.36) CA2SMN1; SMN2CA9BCL2L1BAK1
SCHEMBL31594518 0.84 CA2 (0.53) CA2SMN1; SMN2CA9BCL2L1BAK1
SCHEMBL9051659 0.83 BCL2L1 (0.39) CA2SMN1; SMN2CA9BCL2L1BAK1
SCHEMBL18878046 0.83 NR1I2 (0.49) CA2MGLLSMN1; SMN2CA9CA12
SCHEMBL10823807 0.82 CA1 (0.43) CA2CA9BCL2L1BAK1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1007587-B1 RHEOLOGY MODIFICATION OF ELASTOMERS DOW GLOBAL TECHNOLOGIES INC (US) 2006-04-05 EP claimed
CN-107406379-B Non-explosive bis-sulfonyl azides 戴纳米特诺贝尔爆炸材料和系统工程有限公司 2020-10-16 CN disclosed
EP-3268352-B1 NON EXPLOSIVE BIS-SULFONYL AZIDES DYNAMIT NOBEL GMBH EXPLOSIVSTOFF UND SYSTEMTECHNIK (DE) 2020-06-10 EP disclosed
US-10385016-B2 Non explosive bis-sulfonyl azides DYNAMIT NOBEL GMBH EXPLOSIVSTOFF-UND SYSTEMTECHNIK (DE) 2019-08-20 US disclosed
US-20180050988-A1 NON EXPLOSIVE BIS-SULFONYL AZIDES DYNAMIT NOBEL GMBH EXPLOSIVSTOFF- UND SYSTEMTECHNIK (DE) 2018-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385016-B2 Non explosive bis-sulfonyl azides ARSA, MSRB3, NES CA2 1475/4885MGLL 3839/4885SMN1; SMN2 1193/4885
US-20180050988-A1 NON EXPLOSIVE BIS-SULFONYL AZIDES ARSA, MSRB3, NES CA2 1444/4885MGLL 3856/4885SMN1; SMN2 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.